SCHEMBL1129166

SCHEMBL1129166

COc1cc(Br)c(F)cc1Oc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 0.46
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LTA4H P09960 1/20 0.41
HTR2A P28223 1/20 0.41
SLC6A4 P31645 1/20 0.41
NTRK1 P04629 2/20 0.41
NTRK2 Q16620 2/20 0.41
IGF1R P08069 1/20 0.41
FGFR1 P11362 1/20 0.41
EGFR P00533 1/20 0.40
KDR P35968 1/20 0.40
NTRK3 Q16288 1/20 0.40
CHRNA7 P36544 2/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
TNK2 Q07912 1/20 0.38
KYAT3 Q6YP21 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1129674 0.82 LTA4H (0.41) L3MBTL1LTA4HHTR2ASLC6A4NTRK1
SCHEMBL4573417 0.82 PRKDC (0.48) L3MBTL1HTR2AEGFRKDRLCK
SCHEMBL31085113 0.82 PRKDC (0.48) L3MBTL1HTR2AEGFRKDRLCK
SCHEMBL1129291 0.81 TTR (0.47) TTRALDH1A1MAPK1HTTL3MBTL1
SCHEMBL4564439 0.78 HSPB1 (0.58) ALDH1A1HTTHTR2AKDR
SCHEMBL29025658 0.78 KMT2A (0.50) TTRALDH1A1MAPK1HTTL3MBTL1
SCHEMBL4970541 0.76 CTSV (0.53) ALDH1A1L3MBTL1CHRNA7
SCHEMBL30443242 0.76 CTSV (0.53) ALDH1A1L3MBTL1CHRNA7
SCHEMBL18426437 0.76 CTSV (0.53) ALDH1A1L3MBTL1CHRNA7
SCHEMBL3204868 0.74 EGFR (0.39) EGFRKDRNQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 TTR 575/4885ALDH1A1 292/4885MAPK1 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.